Month: July 2024

Since 2015, the Chinese Society of Clinical Oncology (CSCO) has been dedicated to presenting annual reports on the progress of clinical oncology in China, under the theme "International Standards, Chinese Characteristics, Learning and Innovation." At the recent "2024 Annual Progress in Chinese Clinical Oncology Conference (BOC) and Best of ASCO 2024 China," the latest "Annual Advances in Chinese Clinical Oncology 2023" report was officially released. At this conference, Dr. Zhitao Ying from the Cancer Institute & Hospital Chinese Academy of Medical Sciences presented a detailed report on the advancements in lymphoma research in China for 2023.

In the realm of immunotherapy for lymphoma, PD-1/PD-L1 antibody combination therapies have emerged as a prominent area of research due to their precise modulation of the immune response. These therapies hold immense potential for enhancing efficacy and ensuring safety, providing lymphoma patients with more treatment options and the possibility of improved quality of life and prognosis. At the recent "2024 Nanjing Lymphoma Forum," Dr.  Huiqiang Huang from the Sun Yat-sen University Cancer Center delivered an outstanding presentation titled "Advances in Immunotherapy for Lymphoma: Clinical Exploration of PD-1/PD-L1 Antibody Combination Therapies." Following the forum, "Oncology Frontier - Hematology Frontier" invited Dr.  Huang for an interview to share further insights on this topic.

From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference was successfully held in Bangkok, Thailand. At this year's conference, a study by Dr. Zhangyin Ming's team from the School of Basic Medicine, Tongji Hospital of Huazhong University of Science and Technology, explored "The Role of Platelets in Epithelial-Mesenchymal Transition (EMT) and Tumor Metastasis of Cancer Cells in Situ." "Oncology Frontier - Hematology Frontier" invited Dr. Zhangyin Ming to provide an in-depth analysis of the research content. Here is a detailed summary for our readers.

Patients undergoing hematopoietic stem cell transplantation and high-dose chemotherapy for hematological diseases have impaired immune function, making them highly susceptible to febrile neutropenia and colonization or infection with resistant bacteria. Prompt and accurate initiation of empirical therapy is crucial to improve patient outcomes. At the 2024 European Hematology Association (EHA) Annual Meeting, Dr. Sizhou Feng's team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, reported a study showing a high proportion of bloodstream infections caused by carbapenem-resistant Acinetobacter spp. (CRA) in hematology patients, with homology between bloodstream isolates and colonizing bacteria. This indicates the need to strengthen hospital infection control to reduce resistant bacterial colonization and to promptly initiate appropriate empirical antimicrobial therapy for suspected infections in patients colonized with resistant bacteria. "Oncology Frontier - Hematology Frontier" invited Dr. Sizhou Feng to introduce and interpret this research at the EHA meeting.